| Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) substudy. | |
| | |
MedLine Citation:
|
PMID: 20723851 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: This study sought to determine angiographic and clinical outcomes among patients with acute coronary syndrome (ACS) presenting with isolated anterior ST-segment depression on 12-lead electrocardiogram (ECG). BACKGROUND: In patients with ACS, anterior ST-segment depression on 12-lead ECG may represent plaque rupture with: 1) acute thrombotic occlusion with elevation of cardiac biomarkers (+Tn); 2) a patent artery with +Tn; or 3) a patent artery with -Tn. METHODS: The TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38) enrolled 13,608 ACS patients. Those with isolated anterior (leads V(1) to V(4)) ST-segment depression were analyzed. Angiograms and ECGs were interpreted by local investigators. RESULTS: There were 1,198 (8.8%) patients with isolated anterior ST-segment depression. Of those, 314 (26.2%) had an occluded culprit artery (TIMI flow grade 0/1) and +Tn, 641 (53.5%) had a patent culprit artery (TIMI flow grade 2/3) and +Tn, and 243 (20.3%) had TIMI flow grade 2/3 and -Tn. Among patients with an occluded artery, the culprit artery was most often the left circumflex artery (48.4%). The 30-day incidence of the composite of death and MI was significantly higher among patients with an occluded artery (8.6%) than among those with a patent culprit artery and either +Tn (6.3%) or -Tn (2.9%) (3-way p = 0.006). Among patients with an occluded artery, the median time from ECG to percutaneous coronary intervention was 29.4 h (interquartile range 26.1 to 44.1 h). CONCLUSIONS: Among ACS patients presenting with isolated anterior ST-segment depression, over one-quarter had an occluded culprit artery and elevated cardiac biomarkers. These patients had significantly worse clinical outcomes, and few underwent urgent angiography. |
| | |
Authors:
|
Yuri B Pride; Patricia Tung; Satishkumar Mohanavelu; Cafer Zorkun; Stephen D Wiviott; Elliott M Antman; Robert Giugliano; Eugene Braunwald; C Michael Gibson; |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: JACC. Cardiovascular interventions Volume: 3 ISSN: 1876-7605 ISO Abbreviation: JACC Cardiovasc Interv Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-08-20 Completed Date: 2010-12-13 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101467004 Medline TA: JACC Cardiovasc Interv Country: United States |
Other Details:
|
Languages: eng Pagination: 806-11 Citation Subset: IM |
Copyright Information:
|
Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. |
Affiliation:
|
Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Coronary Syndrome
/
drug therapy,
etiology,
mortality,
radiography,
therapy* Aged Angina, Unstable / drug therapy, etiology, mortality, radiography, therapy* Angioplasty, Balloon, Coronary* / adverse effects, mortality Biological Markers / blood Chi-Square Distribution Coronary Angiography* Coronary Stenosis / complications, drug therapy, mortality, radiography, therapy* Creatine Kinase, MB Form / blood Electrocardiography Female Humans Male Middle Aged Myocardial Infarction / drug therapy, etiology, mortality, radiography, therapy* Piperazines / therapeutic use* Platelet Aggregation Inhibitors / therapeutic use* Proportional Hazards Models Randomized Controlled Trials as Topic Retrospective Studies Risk Assessment Risk Factors Thiophenes / therapeutic use* Time Factors Treatment Outcome Up-Regulation Vascular Patency |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 0/Piperazines; 0/Platelet Aggregation Inhibitors; 0/Thiophenes; 0/prasugrel; EC 2.7.3.2/Creatine Kinase, MB Form |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Impact of bivalirudin therapy in high-risk patients with acute myocardial infarction: 1-year results...
Next Document: Outcomes of percutaneous coronary intervention in intermediate coronary artery disease: fractional f...